Serotonin Receptor Antagonists Sensitize Uveal Melanoma Cells to Oncogenic Pathway Inhibitors
Inhibiting the serotonin receptor HTR2B sensitizes uveal melanoma cells to oncogenic Gαq-Q209L/P inhibitors by promoting an inactive mutant conformation.
Inhibiting the serotonin receptor HTR2B sensitizes uveal melanoma cells to oncogenic Gαq-Q209L/P inhibitors by promoting an inactive mutant conformation.
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.